Zusammenfassung
Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente zur Behandlung von Essstörungen und Adipositas im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Attia E, Steinglass JE, Walsh BT et al (2019) Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial. Am J Psychiatry 176:449–456
AWMF Online (2019) S3-Leitlinie „Diagnostik und Therapie der Essstörungen“. https://www.awmf.org/leitlinien/detail/ll/051-026.html. Zugegriffen: 25. Mai 2023
Brewerton TD, D’Agostino M (2017) Adjunctive use of olanzapine in the treatment of avoidant restrictive food intake dDisorder in children and adolescents in an eating disorders program. J Child Adolesc Psychopharmacol 27:920–922
Chao AM, Wadden TA, Walsh OA et al (2019) Changes in health-related quality of life with intensive behavioural therapy combined with liraglutide 3.0 mg per day. Clin Obes 9:12340
Durrer Schutz D, Busetto L, Dicker D et al (2019) European practical and patient-centred guidelines for adult obesity management in primary care. Obes Facts 12:40–66
Gray E, Chen T, Menzel J et al (2018) Mirtazapine and weight gain in avoidant and restrictive food intake disorder. J Am Acad Child Adolesc Psychiatry 57:288–289
Hayes MR, Schmidt HD (2016) GLP-1 influences food and drug reward. Curr Opin Behav Sci 9:66–70
Heymsfield SB, Coleman LA, Miller R et al (2021) Effect of Bimagrumab vspPlacebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open 4:e2033457
Himmerich H, Treasure J (2018) Psychopharmacological advances in eating disorders. Expert Rev Clin Pharmacol 11:95–108
Himmerich H, Minkwitz J, Kirkby KC (2015) Weight gain and metabolic changes during treatment with antipsychotics and antidepressants. Endocr Metab Immune Disord Drug Targets 15(4):252–260
Himmerich H, Joaquim M, Bentley J et al (2018) Psychopharmacological options for adult patients with anorexia nervosa: the patients’ and carers’ perspectives. CNS Spectr 23:251–252
Himmerich H, Bentley J, Kan C, Treasure J (2019) Genetic risk factors for eating disorders: an update and insights into pathophysiology. Ther Adv Psychopharmacol 9:2045125318814734
Himmerich H, Lewis YD, Conti C et al (2023on) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders. World J Biol Psychiatry doi: https://doi.org/10.1080/15622975.2023.2179663. Online ahead of print
Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387:205–216
Jastreboff AM, Kaplan LM, Frías JP et al (2023) Triple-hormone-receptor agonist retatrutide for obesity – a phase 2 trial. N Engl J Med 389(6):514-526 (Epub 2023 Jun 26)
Keeler JL, Treasure J, Juruena MF et al (2021) Ketamine as a treatment for anorexia nervosa: a narrative review. Nutrients 13:4158
Larsen JR, Vedtofte L, Jakobsen MSL et al (2017) Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry 74:719–728
Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322
Lee H, Rhee PL, Park EH et al (2007) Clinical outcome of rumination syndrome in adults without psychiatric illness: a prospective study. J Gastroenterol Hepatol 22:1741–1747
Mahr F, Billman M, Essayli JH, Lane Loney SE (2022) Selective serotonin reuptake inhibitors and hydroxyzine in the treatment of avoidant/restrictive food intake disorder in children and adolescents: rationale and evidence. J Child Adolesc Psychopharmacol 32:117–121
McElroy SL, Hudson JI, Mitchell JE et al (2015) Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry 72:235–246
McElroy SL, Guerdjikova AI, Mori N, Romo-Nava F (2019) Progress in developing pharmacologic agents to treat bulimia nervosa. CNS Drugs 33:31–46
Milos G, Antel J, Kaufmann LK et al (2020) Short-term metreleptin treatment of patients with anorexia nervosa: rapid on-set of beneficial cognitive, emotional, and behavioral effects. Transl Psychiatry 10:303
Qasim A, Turcotte M, de Souza RJ et al (2018) On the origin of obesity: identifying the biological, environmental and cultural drivers of genetic risk among human populations. Obes Rev 19:121–149
Pauwels A, Broers C, Van Houtte B et al (2018) A randomized double-blind, placebo-controlled, cross-over study using Baclofen in the treatment of rumination syndrome. Am J Gastroenterol 113:97–104
le Roux CW, Astrup A, Fujioka K et al (2017) 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a andomized, double-blind trial. Lancet 389:1399–1409
San K, Fogel J, Khazron D (2023) Retrospective analysis of hospitalized patients with type 2 diabetes mellitus treated with glucagon-like peptide 1 receptor agonist therapy. South Med J 116:231–236
Safer DL, Adler S, Dalai SS et al (2020) A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa. Int J Eat Disord 53:266–277
Singh AK, Singh R (2020) Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol 13:53–64
Siskind DJ, Russell AW, Gamble C et al (2018) Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX). Diabetes Obes Metab 20:1050–1055
Spriggs MJ, Douglass HM, Park RJ et al (2021) Study protocol for „Psilocybin as a treatment for anorexia nervosa: a pilot study“. Front Psychiatry 12:735523
Vachhani H, Ribeiro BS, Schey R (2020) Rumination syndrome: recognition and treatment. Curr Treat Options Gastroenterol. https://doi.org/10.1007/s11938-020-00272-4
Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly Semaglutide in adults with overweight or obesity. N Engl J Med 384:989–1002
Yang Z, Lv Y, Yu M et al (2022) GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS. Front Pharmacol 13:925377
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Himmerich, H., Benkert, O. (2023). Medikamente zur Behandlung von Essstörungen und Adipositas. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67685-1_9
Download citation
DOI: https://doi.org/10.1007/978-3-662-67685-1_9
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-67684-4
Online ISBN: 978-3-662-67685-1
eBook Packages: Medicine (German Language)